![Page 1: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/1.jpg)
Basics of HIV Management 2010
Dr. Dennis Sifris
LifeSense Disease Management
![Page 2: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/2.jpg)
Basics of HIV Management 2010
1. When to start ARV therapy
2. Recommended ARV regimens
3. Monitoring progress and adherence
4. When to change to second regimen
5. Adverse events
6. TB/HIV, non-HIV-related morbidity, PEP, MTCT
![Page 3: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/3.jpg)
Module 1
![Page 4: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/4.jpg)
New WHO Guidelines 2010
• It promotes earlier treatment, recommending starting HIV treatment at 350 cells or below.
• It recommends moving to more patient-friendly and less toxic regimens, phasing out stavudine (d4T), which is more toxic than initially thought.
• It recommends starting co-infected people with TB (or hepatitis B if it requires treatment) on ART earlier, regardless of the CD4 count.
• It acknowledges the prevention benefits of treatment (i.e. HAART is prevention).
![Page 5: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/5.jpg)
2010 Universal Shift
EARLY INITIATION OF ARVs
![Page 6: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/6.jpg)
Benefits of Early ARV Treatment
• Earlier suppression of viral replication
• Lower risk of detrimental viral evolution
• Lower risk of virologic failure
• Preservation of immune function
• Prolongation of disease-free survival
• Decrease in the risk of HIV transmission
• Decrease of non-HIV related morbidity
![Page 7: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/7.jpg)
Case for Earlier Initiation of Therapy
• Availability of more potent, easier, and less toxic regimens
• Cohort studies showing benefit with earlier therapy
• Better response to therapy
• Decreased transmission of HIV
• Preserve R5-tropic virus
• Cost efficacy
![Page 8: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/8.jpg)
Early vs. Late Cost efficacy
![Page 9: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/9.jpg)
Starting HAART: When to take the first step
Data backing up early initiation
1. START Study
2. CASCADE Study
3. CHARTER Study
4. CHER Study (paediatrics)
![Page 10: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/10.jpg)
START Study
• 3 arms by CD4 stratification – <350
– 350- 500
– >500
• Significant advantage in arms 1 and 2 but no real advantage in arm 3 (>500)
• Ongoing
![Page 11: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/11.jpg)
CASCADE-1
AIDS 2010: THLBB201
![Page 12: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/12.jpg)
CASCADE-2
AIDS 2010: THLBB201
![Page 13: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/13.jpg)
Data supporting Early Initiation
CHER STUDY
• Ongoing South African paediatric study
• Huge benefit of immediate starting of HAART in children vs. delayed treatment
• Better clinical outcome, as well as cost efficacy
![Page 14: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/14.jpg)
When to Start ART: CHER Analysis
![Page 15: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/15.jpg)
Data supporting Early Initiation
CAMELIA STUDY (Cambodia)
• With TB co-infection when is the best time to start ARVS
• Starting ARVs within 2 weeks of TB Rx decreased death from TB by a third
• 72% of TBs did not know their status
![Page 16: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/16.jpg)
When to Start ART- The CAMELIA Trial (TB)
![Page 17: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/17.jpg)
Conclusion HIV/TB Co-infection
• Treat TB immediately
• Introduce ARVs as soon as the patient has settled on the TB Rx and can tolerate the ARVs
• 2 weeks is optimal period irrespective of CD4 count
![Page 18: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/18.jpg)
Data supporting Early Initiation
CHARTER STUDY • Higher incidence of neuro-cognitive disorders with
very low CD4 (nadir of < 50)
• Even after treatment with HAART, irreversible damage persists
![Page 19: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/19.jpg)
Starting ARVs by CD4 count
• < 350 Start HAART • 350-500 Consider if patient ready and willing • > 500 Defer HAART With following exceptions: • TB Start HAART at any CD4 count • Pregnancy <350 lifelong HAART >350 MTCT Start ARVs on presentation
![Page 20: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/20.jpg)
The Big Question:
Why are so many South Africans still reluctant to start HAART?
![Page 21: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/21.jpg)
Obstacles High rates of “lost to follow-up” Major reasons include
• Advanced disease (late presentation) • Culture of denial still exists post-Mbeki • 51% of Americans still consider HIV a terminal illness • Co-payment for services • Hidden costs (e.g. 50% costs for transportation to
and from clinics) • Shortages in ARVs at clinics • Poor healthcare infrastructure • Traditional healers
![Page 22: Basics of HIV Management 2010Data backing up early initiation . 1. START Study 2. CASCADE Study . 3. CHARTER Study 4. CHER Study (paediatrics) START Study •3 arms by CD4 stratification](https://reader035.vdocuments.site/reader035/viewer/2022070819/5f1b920657a427707b571047/html5/thumbnails/22.jpg)
In Summary • Encourage patients to start ARVs early • “Patient readiness” is often overemphasized • Delay of ARVs will cause future problems • Explain benefits of early intervention • Newer ARVs have are less toxic and more tolerable • More treatment options now available • Normal life expectancy is possible • HAART as prevention